open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

Efficiency of liposomal doxorubicin in the treatment of advanced breast cancer after completed conventional doxorubicin cumulative dose

Michał Tomala

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Liposomal doxorubicin is indicated for the treatment of advanced breast cancer. In combination with cyclophosphamide is an effective alternative in first-line treatment. However, it can also be successfully used in subsequent lines of chemotherapy. This paper presents a case study of patient treated with the above regimen in the third-line therapy, after exceeding the cumulative dose of classic doxorubicin.
Onkol. Prak. Klin. 2010; supl. A: A37–A39

Abstract

Liposomal doxorubicin is indicated for the treatment of advanced breast cancer. In combination with cyclophosphamide is an effective alternative in first-line treatment. However, it can also be successfully used in subsequent lines of chemotherapy. This paper presents a case study of patient treated with the above regimen in the third-line therapy, after exceeding the cumulative dose of classic doxorubicin.
Onkol. Prak. Klin. 2010; supl. A: A37–A39
Get Citation

Keywords

liposomal doxorubicin; cardiotoxicity; breast cancer

About this article
Title

Efficiency of liposomal doxorubicin in the treatment of advanced breast cancer after completed conventional doxorubicin cumulative dose

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

37-39

Published online

2010-11-22

Keywords

liposomal doxorubicin
cardiotoxicity
breast cancer

Authors

Michał Tomala

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl